Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.48 |
| ▸ | CTSS | P25774 | 7/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9910753 | 1.00 | CTSK (0.48) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL25168226 | 1.00 | CTSK (0.48) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL18755031 | 0.82 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL10190348 | 0.82 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL1536360 | 0.82 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL18799498 | 0.82 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL12556753 | 0.80 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL31407815 | 0.79 | CTSK (0.47) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL31407801 | 0.79 | CTSK (0.47) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL12130746 | 0.79 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212167-B2 | Mitochondrial targeted stimulators of apoptosis | THE ROCKEFELLER UNIVERSITY (US) | 2015-12-15 | — | — | US | disclosed |
| US-20130244325-A1 | MITOCHONDRIAL TARGETED STIMULATORS OF APOPTOSIS | THE ROCKEFELLER UNIVERSITY (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2010138666-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244325-A1 | MITOCHONDRIAL TARGETED STIMULATORS OF APOPTOSIS | AIFM1, BID, TFAM | CTSK 3026/4885CTSS 2027/4885CA1 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.